Skip to main content
SpringerLink
Log in

Three dimensional conformal radiotherapy in patients with T2a-b, N0, M0 prostatic carcinoma

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

The current study was undertaken to evaluate the Prostate Specific Antigen (PSA) relapse free survival and the prognostic factors in a total of 38 patients with stages of T2a-b, N0, M0 prostate carcinoma treated with three-dimensional conformal radiotherapy (3D-CRT). Mean 69.63 Gy was given with 3D-CRT, the mean follow up time was 13.89 months, and the mean prebiopsied PSA level was 25.12 ng/ml. The 2-year PSA relapse free survival was 47.37% for the entire group. The 2-year PSA relapse free survival rates were 100% and 44.74% for the patients with Gleason score ≤ 7 and greater than 7 (p ≤ 0.05). Patients with prebiopsied PSA level ≤ 10 ng/ml and the stages of T2a or T2b did not show any significant differences (p ≥ 0.05). Although the few case number and short term follow up, in this study 3D-CRT was a new effective technique to prostate cancer for our institutes and the Gleason score was important predictor of PSA relapse free survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hanks GE, Martz KL, Diamond JJ. The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 1988; 15: 1299.

    PubMed  CAS  Google Scholar 

  2. Smit WGJM, Helle PA, van Putten WIJ, Wiznmalalen AJ, Seldenrath JJ, ven Der Werf-Messing BHP. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 1990; 18: 23.

    PubMed  CAS  Google Scholar 

  3. Fukanja-Johnson N, Sandler HM, McLaughlin PW et al. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 38: 311.

    Article  Google Scholar 

  4. Zelefsky MJ, Happersett L, Leibel SA et al. The effect of treatment positioning on normal tissue dose in patients with prostate cancer treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 1997; 37: 13.

    Article  PubMed  CAS  Google Scholar 

  5. Zelefsky MJ, Fuks Z, Wolfe T. et al. Locally advanced prostatic cancer: Long-term toxicity outcome after threedimensional conformal radiation therapy - a dose - escalation study. Radiology 1998; 209: 169.

    PubMed  CAS  Google Scholar 

  6. Zelefsky MJ, Cowen D, Kuks Z et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999; 85(11): 2460.

    Article  PubMed  CAS  Google Scholar 

  7. Zelefsky MJ, Lyass O, Fuks Z et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and threedimensional conformal radiotherapy. J Clin Oncol 1998; 16(10): 3380.

    PubMed  CAS  Google Scholar 

  8. Lee WR, Hanlon AL, Hanks GE. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease free survival. J Urol 1996; 156: 450.

    Article  PubMed  CAS  Google Scholar 

  9. Leibel SA, Zelefsky MJ, Kutcher GJ et al. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: Interm report of a phase I dose escalation study. J Urol 1994; 152: 1792.

    PubMed  CAS  Google Scholar 

  10. Beahrs OH, Henson DE, Hutter RVP, Kenedy BJ. Manual for Staging of Cancer. Philadelphia: JB Lippincott, 1992.

    Google Scholar 

  11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 447.

    Article  Google Scholar 

  12. Jewett HJ. Radical perineal prostatectomy for palpable, clinically localized, nonobstructive cancer: experience at the Johns Hopkins Hospital 1909-1963. J Urol 1980; 124: 492.

    PubMed  CAS  Google Scholar 

  13. Catalona WJ, Bigg SW. Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol 1990; 143: 538.

    PubMed  CAS  Google Scholar 

  14. George NJR. Natural history of localized prostatic cancer managed by conservative therapy alone. Lancet 1988; 1(2584): 494.

    Article  PubMed  CAS  Google Scholar 

  15. Burman C, Chui CS, Kutcher G, Leibel S et al. Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1999; 39(4): 863.

    Article  Google Scholar 

  16. Zelefsky MJ, Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer: reducing the potential morbidity of therapy. Urology 1997; 49: 38.

    Article  PubMed  CAS  Google Scholar 

  17. Laverdiere J, Gomez JL, Cusan L et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiotherapy in localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 247.

    Article  PubMed  CAS  Google Scholar 

  18. Zelefsky MJ, Wallner KE, Ling CC, Raben A et al. Comparison of the 5-year outcome and morbidity of threedimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 1999; 17(2): 517.

    PubMed  CAS  Google Scholar 

  19. Perez CA, Garcia D, Simpson JR et al. Factors influencing outcome of definitive radiotherapy for localized carcinoma of the prostate. Radiother Oncol 1989; 16: 1.

    Article  PubMed  CAS  Google Scholar 

  20. Landmann C, Hunig H. Prostatic specific antigen as an indicator of response to radiotherapy in prostate cancer. Int J Radiat Oncol Biol Phys 1989; 17: 1073.

    PubMed  CAS  Google Scholar 

  21. Bagshaw MA, Kaplan ID, Cox RC. Radiation therapy for localized disease. Cancer 1993; 71: 939.

    Article  PubMed  CAS  Google Scholar 

  22. Hanks GE, Lee WR, Hanlon AL et al. Conformal technique dose escalation for prostate cancer: chemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ⩾ 10 ng/ml. Int J Radiat Oncol Biol Phys 1996; 35: 861.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Cebeci Hospital, Ankara University Medical Faculty, Ankara, Turkey

    Cengiz Kurtman, Binnaz Çelebioğlu & Meltem Nalca Andrieu

  2. Department of Urology, İbn-i Sina Hospital, Ankara University Medical Faculty, Ankara, Turkey

    Orhan Göğüş

Authors
  1. Cengiz Kurtman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Binnaz Çelebioğlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Orhan Göğüş
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Meltem Nalca Andrieu
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kurtman, C., Çelebioğlu, B., Göğüş, O. et al. Three dimensional conformal radiotherapy in patients with T2a-b, N0, M0 prostatic carcinoma. Int Urol Nephrol 32, 275–278 (2000). https://doi.org/10.1023/A:1007174213087

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1007174213087

Search

Navigation